Warnings on Cleveland-Cliffs, Chevron, and Wendy's
The stock market’s V-shaped recovery since “Liberation Day” lifted speculative sectors. Investors should exercise caution with the mining sector.Cleveland-Cliffs (CLF) said on May 2 that it would idle its Conshohocken, Riverdale, and Steelton steel mills indefinitely. Starting this summer, the idling will affect around 950 workers.CLF stock will face ongoing selling pressure. The firm had aspirations of buying U.S. Steel (X). Last November 2024, the firm completed its acquisition of Stelco. It paid CAD 60 a share and 0.454 shares of Cliffs common stock.Chevron (CVX) shares are near a 52-week low. The firm reported $47.61 billion in revenue (-2.3% Y/Y). The dividend of $1.71 yields 4.77% for shareholders. The firm bought back significant amounts of shares through the $2.2 billion purchase of Hess stock.CVX stock is attractive, thanks to the company’s strong management team. The stock will recover once oil prices bounce back.Wendy’s (WEN) risks falling below its 52-week low. The firm cut its dividend by 44% to $0.14. This is still a 4.5% forward yield. Investors may also consider McDonald’s (MCD) and Chipotle (CMG), whose brand power drives customer traffic. Starbucks (SBUX), DoorDash (DASH), and Yum Brands (YUM) are also well-run restaurant service firms to consider holding.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


